Alpha Antichymotrypsin Polyclonal antibody

Alpha Antichymotrypsin Polyclonal Antibody for FC, IHC, IP, WB,ELISA

Host / Isotype

Rabbit / IgG

Reactivity

human and More (2)

Applications

WB, IP, IHC, FC, ELISA

Conjugate

Unconjugated

Cat no : 12192-1-AP

Synonyms

A1 Antichymotrypsin, A-1-Antichymotrypsin, AACT, ACT, Alpha 1 antichymotrypsin, GIG24, GIG25, Serpin A3, SERPINA3



Tested Applications

Positive WB detected inhuman blood tissue, COLO 320 cells, human colon tissue
Positive IP detected inCOLO 320 cells
Positive IHC detected inhuman tonsillitis tissue, human liver tissue, human spleen tissue
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
Positive FC detected inHepG2 cells

Recommended dilution

ApplicationDilution
Western Blot (WB)WB : 1:500-1:1000
Immunoprecipitation (IP)IP : 0.5-4.0 ug for IP and 1:500-1:1000 for WB
Immunohistochemistry (IHC)IHC : 1:50-1:500
Sample-dependent, check data in validation data gallery

Product Information

12192-1-AP targets Alpha Antichymotrypsin in WB, IP, IHC, FC, ELISA applications and shows reactivity with human samples.

Tested Reactivity human
Cited Reactivityhuman, mouse, rat
Host / Isotype Rabbit / IgG
Class Polyclonal
Type Antibody
Immunogen Alpha Antichymotrypsin fusion protein Ag2830
Full Name serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 3
Calculated molecular weight 448 aa, 48 kDa
Observed molecular weight 44-70 kDa
GenBank accession numberBC010530
Gene symbol SERPINA3
Gene ID (NCBI) 12
Conjugate Unconjugated
Form Liquid
Purification Method Antigen affinity purification
Storage Buffer PBS with 0.02% sodium azide and 50% glycerol pH 7.3.
Storage ConditionsStore at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.

Background Information

Human SerpinA3, also known as Alpha 1-antichymotrypsin (AACT), is a member of the serine protease inhibitor class, and is a plasma alpha globulin glycoprotein which increases in the blood during the inflammatory process. SerpinA3, is also an inhibitor of neutrophil cathepsin G, mast cell chymases and pancreatic chymotrypsin. SerpinA3 is produced primarily in the liver, and is identified as an acute-phase inflammatory protein. SerpinA3 deficiency has been associated with liver disease. SerpinA3 has also been implicated in the pathology of a number of devastating human diseases including chronic obstructive pulmonary disease (COPD), Parkinson's disease (PD), Alzheimer's disease (AD), Stroke, Cystic Fibrosis, Cerebral Haemorrhage and Multiple System Atrophy.

Protocols

Product Specific Protocols
WB protocol for Alpha Antichymotrypsin antibody 12192-1-APDownload protocol
IHC protocol for Alpha Antichymotrypsin antibody 12192-1-APDownload protocol
IP protocol for Alpha Antichymotrypsin antibody 12192-1-APDownload protocol
FC protocol for Alpha Antichymotrypsin antibody 12192-1-APDownload protocol
Standard Protocols
Click here to view our Standard Protocols

Publications

SpeciesApplicationTitle
humanWB

Front Immunol

Screening and identification of tissue-infiltrating immune cells and genes for patients with emphysema phenotype of COPD

Authors - Di Wang
humanWB,IHC

Br J Cancer

Identification of GlcNAcylated alpha-1-antichymotrypsin as an early biomarker in human non-small-cell lung cancer by quantitative proteomic analysis with two lectins.

Authors - Yanxia Jin
mouseIHC

Front Med (Lausanne)

An Integrated Proteomics and Metabolomics Strategy for the Mechanism of Calcium Oxalate Crystal-Induced Kidney Injury.

Authors - Songyan Gao

Proteomics Clin Appl

Serum protein profiling in diffuse large B-cell lymphoma.

Authors - Jacques Riby
human,ratWB

Food Funct

Sinensetin attenuates IL-1β-induced cartilage damage and ameliorates osteoarthritis by regulating SERPINA3

Authors - Zhendong Liu
humanWB

Acta Neuropathol Commun

Synaptic proteomics reveal distinct molecular signatures of cognitive change and C9ORF72 repeat expansion in the human ALS cortex

Authors - Zsofia I. Laszlo